Analysis of Virus Clearance for Biotechnology Manufacturing Processes from Early to Late Phase Development.

The risk for virus contamination in biotechnology products (e.g., monoclonal antibodies, fusion proteins, or antibody-drug conjugates) derived from mammalian cell lines is a safety concern that must be evaluated from the early stages of development.